Prescrire Int. 2009 Apr;18(100):59.
In a trial involving patients with advanced-stage liver cancer but unimpaired hepatic function, sorafenib increased the median survival time by about 3 months in half of patients, but provoked frequent adverse effects.
在一项针对晚期肝癌但肝功能未受损患者的试验中，索拉非尼使一半患者的中位生存时间延长了约3个月，但引发了频繁的不良反应。
Zotero 插件